Physician profile
Melwin Joseph
NPI 1245720671
$747.98
in general payments reported to CMS, 2019-2025
17 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.48 · 2021: $48.95 · 2022: $148 · 2023: $154 · 2024: $131 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $124.70 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $94.12 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $92.43 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $68.24 | 2022-2025 | |
| Seqirus USA INC | $64.25 | 2025 | Fluad, Flucelvax |
| Novartis Pharmaceuticals Corporation | $47.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.14 | 2024 | Cobenfy |
| Gilead Sciences, INC. | $31.28 | 2023-2024 | |
| Csl Behring | $25.56 | 2021 | |
| Celgene Corporation | $25.48 | 2019 | |
| Abbott Laboratories | $23.98 | 2025 | Proclaim |
| Teva Pharmaceuticals USA, INC. | $23.02 | 2024 | Uzedy |
| Janssen Pharmaceuticals, INC | $22.11 | 2023 | Xarelto |
| Smith+Nephew, INC. | $18.55 | 2022 | |
| Exact Sciences Corporation | $16.26 | 2025 | The Cologuard Plus Collection Kit |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $16.15 | 2025 | Ibsrela |
| Hologic Sales and Service, LLC | $14.97 | 2024 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melwin Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.